The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...
OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years ...
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.
A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs ...
A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training ...
HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib ...
Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.
In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.
Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback